MedPath

Strepsils Extra Triple Action Blackcurrant Lozenges

Marketing Authorization Holder: Reckitt Benckiser Healthcare (UK) Ltd Slough SL1 3UH

Authorised
Legal Category

General Sales List

ATC Code

Not classified

Authorization Number

PL 00063/0392

Summary of Product Characteristics

Detailed prescribing information and pharmaceutical guidance from the UK Electronic Medicines Compendium.

Composition

Active and inactive ingredients

Each lozenge contains Hexylresorcinol 2.4mg Excipient(s) with known effect: Glucose Fragrance containing allergens - d-Limonene and Linalool\\ Carmoisine (E122) Sucrose Sulphites – Sulphur Dioxide (E220)\* Wheat starch (containing Gluten)\* Propylene glycol \\ \* present in liquid glucose \\ present in blackcurrant flavour For excipients see Section 6.1

Pharmaceutical Form

Dosage form and administration route

Lozenge A round purple lozenge

Clinical Particulars

Therapeutic indications and usage

4.1 Therapeutic indications As an antiseptic and local anaesthetic for the relief of sore throat and its associated pain.4.2 Posology and method of administration For oral administration. Adults, the elderly and children 6 years and over: One lozenge dissolved slowly in the mouth every three hours or as required. Do not take more than 12 lozenges in 24 hours. Not to be given to children under 6 years.4.3 Contraindications Hypersensitivity to any of the ingredients.4.4 Special warnings and precautions for use The label will convey: Keep out of the reach and sight of children. If symptoms persist consult your doctor. Not to be given to children under 6 years. **Important information about some of the ingredients of this medicine** • This medicine contains only very low levels of gluten (from wheat starch). It is regarded as 'gluten-free' and is very unlikely to cause problems if you have coeliac disease. One lozenge contains no more than 22.42 micrograms of gluten. If you have wheat allergy (different from coeliac disease) you should not take this medicine. • This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially 'sodium-free'. • This medicine contains fragrance with d-Limonene and Linalool. d-Limonene and Linalool may cause allergic reactions. • This medicine contains carmoisine (E122) which may cause allergic reactions • This medicine contains Sulphites – Sulphur Dioxide (E220) – present in liquid glucose which may rarely cause severe hypersensitivity reactions and bronchospasm. • Patients with rare glucose-galactose malabsorption should not take this medicine • Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.4.5 Interaction with other medicinal products and other forms of interaction None known.4.6 Pregnancy and lactation There is lack of evidence of safety of the product in human pregnancy and in animals, but hexylresorcinol has been used widely in lozenges for many years without apparent ill consequence. However, as with all medicines, caution should be exercised during pregnancy and lactation.4.7 Effects on ability to drive and use machines None known.4.8 Undesirable effects | | | | | --- | --- | --- | | **System Organ Class** | **Frequency** | **Adverse Events** | | Immune System Disorders | Not known | Hypersensitivity1 | 1 Hypersensitivity reactions may include rash, urticaria and angioedema, which may include swelling of the face, neck, throat or tongue that could affect breathing. **Reporting of Suspected Adverse Reactions** Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.4.9 Overdose Hexylresorcinol overdosage may cause minor gastrointestinal irritation. Treatment would be withdrawal of the product and symptomatic measures as appropriate.

Pharmacological Properties

Pharmacodynamics and pharmacokinetics

5.1 Pharmacodynamic properties Hexylresorcinol is a local anaesthetic for topical use on the mucous membranes of the mouth and throat. Mild antiseptic activity has also been demonstrated. The product base has a demulcent action.5.2 Pharmacokinetic properties Pharmacokinetic considerations do not arise since the pharmacological action is local to the oro-pharyngeal cavity.5.3 Preclinical safety data There are no preclinical data of relevance additional to those already included in other sections of the SPC.

Pharmaceutical Particulars

Storage and handling information

6.1 List of excipients Liquid sucrose Liquid glucose (prepared from wheat starch (containing gluten) and Sulphites – Sulphur Dioxide) Blackcurrant flavour (containing Propylene glycol, d-Limonene and Linalool) Levomenthol Carmoisine (E122) Patent blue V (E131)6.2 Incompatibilities Not applicable6.3 Shelf life 36 months for the unopened blister pack6.4 Special precautions for storage Do not store above 25°C. Store in the original packaging. Keep in the outer carton.6.5 Nature and contents of container Blister packs of 250 micron PVC/coated 40gsm PVDC with 20 micron hard temper aluminium foil heat-sealed to the PVC/PVDC blister. The tray contains an appropriate number of lozenges to give a pack sizes of 2, 4, 6, 12, 16, 24, 32, 36 and 48. 8 lozenges in a blister in a carton or a flow wrap outer composed of PET/aluminium foil/polyethylene.6.6 Special precautions for disposal and other handling None specific to the product/pack.

Last updated: 23/08/2021

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.